Background Activation of the PI3K-Akt-mTOR signaling pathway is common in advanced
castration resistant prostate cancer (CRPC), typically through PTEN loss. Preclinical studies …

Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …

Background Despite frequent PTEN (phosphatase and tensin homologue) loss and
Akt/mammalian target of rapamycin (mTOR) signaling in prostate cancer, the disease is …

Background Few options are available after taxane-based therapy in men with CRPC.
Genetic alterations involving the mTOR pathway have been associated with CRPC …

BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

Background The progression of prostate cancer to castration-resistant prostate cancer
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …

Background: The mammalian target of rapamycin (mTOR) pathway is deregulated in
castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of …

Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition …

Background The PTEN tumor suppressor is frequently lost in CRPC, with activation of Akt-
mTOR signaling, driving growth. We conducted a phase I trial of the mTOR inhibitor …

Background MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform
standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was …